Back to the cluster overview

Hallmark 4 of 12

Loss of proteostasis

A cell produces proteins continuously, and each of them must fold into a precise three-dimensional shape. An entire network of helper proteins and degradation pathways ensures that misfolded copies are corrected or disposed of. This network is called proteostasis. It loses capacity with age, and the consequences are described in considerable detail for several diseases.

Scientific term
Loss of proteostasis
Group
Primary causes
Hallmarks of Aging
Described in 2013

The hallmarks of aging are a research framework, not a diagnostic tool. They describe processes that occur during ageing, but they do not prove causation and are not a basis for medical decisions.

What lies behind it

The proteostasis network has three jobs: fold correctly, repair what is misfolded, degrade what cannot be saved. Chaperones handle folding, above all the heat shock proteins. They bind to freshly emerging chains and prevent sticky segments from pairing with the wrong partners.

There are two main degradation routes. The ubiquitin-proteasome system tags individual proteins with a ubiquitin chain and feeds them into a barrel-shaped degradation machine. Larger aggregates and whole organelles go through autophagy, which is listed as a hallmark in its own right. Both routes lose throughput with age.

Added to this are stress responses that fire under overload: the heat shock response in the cytoplasm and the unfolded protein response in the endoplasmic reticulum. Both react more sluggishly and weakly in the ageing organism, which widens the capacity gap.

If misfolded proteins remain, they clump together. The characteristic form is the beta-sheet structure that builds amyloid fibrils: very stable, hard to degrade and able to force further molecules into the same misfolding. This exact structure is found in amyloid beta in Alzheimer’s, in alpha-synuclein in Parkinson’s and in transthyretin in transthyretin amyloidosis.

How robust is the evidence

Moderate evidence

The mechanism is well documented; human data are largely observational.

Cell biological evidence is strong. Chaperone activity, proteasome throughput and the capacity of stress responses demonstrably decline in aged tissue, and in model organisms strengthening these systems extends lifespan. This has been shown repeatedly in Caenorhabditis elegans and in Drosophila.

In humans the most convincing evidence is indirect and comes from therapy. In transthyretin amyloidosis with cardiomyopathy, the compound tafamidis stabilises the transthyretin tetramer and thereby prevents its breakdown into misfolding-prone fragments. In a randomised trial this reduced mortality and cardiovascular hospitalisations. That shows an intervention in protein folding can improve hard endpoints in an age-associated disease.

For Alzheimer’s the picture is more complicated and is frequently overstated. Antibodies against amyloid beta remove plaques reliably, but the clinical effect on cognitive trajectory in the licensing trials is small and comes with relevant side effects. That suggests protein aggregation is involved but is not the sole cause.

Findings in humans

  • Chaperone activity and proteasome throughput are measurably reduced in aged human tissue.
  • Tafamidis stabilises transthyretin and reduced mortality and hospitalisations in a randomised trial in transthyretin amyloidosis.
  • Amyloid beta, alpha-synuclein and transthyretin form the same beta-sheet structure, which is hard to degrade.
  • Anti-amyloid antibodies remove plaques reliably but improve cognitive trajectory only slightly.
  • In Caenorhabditis elegans and Drosophila, strengthening proteostasis systems extends lifespan.

What of this is measurable at YEARS

Not measurable in preventive care

The functional capacity of the proteostasis network cannot be determined in a living person. There is no blood test for chaperone capacity or proteasome throughput. What appears in the YEARS laboratory touches on protein metabolism and nutritional status but says nothing about quality control itself.

Total protein, albumin and prealbumin

These values describe protein supply and the synthetic capacity of the liver. A low albumin is a known risk marker and feeds into PhenoAge. It says nothing about folding or degradation of proteins inside the cell.

Amino acid analysis

Shows the availability of the building blocks from which proteins are made. Relevant for nutritional counselling, particularly with low protein intake in older age. No inference about cellular quality control can be drawn from it.

Serum electrophoresis and immunofixation

Detects monoclonal proteins. This matters diagnostically because light-chain amyloidosis can surface this way. It is a targeted search for disease, not an assessment of proteostasis.

Context

No laboratory value in preventive care reflects proteostasis. Anyone selling a capsule with the promise of improving cellular protein quality control can neither measure nor demonstrate that effect in you.

Limits of this hallmark

Translation from model organism to human is particularly delicate here. Nematodes and flies have lifespans of days to weeks and barely divide after development. That a strengthened heat shock response buys them weeks of life says little about decades in humans.

The link to neurodegenerative disease is frequently used as proof of the hallmark although it can be read both ways. Amyloid plaques are also found in substantial quantity in cognitively unimpaired older people. Aggregation alone therefore does not explain the clinical course.

Practically, there is no follow-through. No generally applicable intervention demonstrably improves proteostasis in healthy people. What works in trials targets a single protein, tafamidis and transthyretin for instance, and is tied to a specific diagnosis.

Frequently asked questions

What does proteostasis mean?→

Proteostasis is the totality of processes by which a cell keeps its proteins in working order. It covers three jobs: newly formed protein chains must fold correctly into their three-dimensional shape, misfolded copies should be corrected where possible, and whatever cannot be saved must be degraded. Helper proteins called chaperones support folding. Degradation is handled by the ubiquitin-proteasome system and by autophagy. With age the capacity of all these components declines. Misfolded proteins then remain more often and can clump into aggregates that are hard to break down.

Is Alzheimer’s linked to disturbed proteostasis?→

A link exists, but its significance is contested. In Alzheimer’s, amyloid beta deposits outside cells while tau protein forms tangles inside them. Both are misfolding products that functioning quality control should intercept. Two things argue against reading this as the sole cause. First, amyloid plaques are also found in substantial quantity in older people without cognitive impairment. Second, while anti-amyloid antibodies remove plaques reliably, the effect on cognitive trajectory in the licensing trials remains small and comes with relevant side effects. Protein aggregation is therefore involved but does not fully explain the disease.

Can proteostasis be measured?→

Not in a living person. Chaperone capacity and proteasome throughput can be determined in cell culture and tissue samples, but not through a blood test in preventive care. Values such as total protein, albumin or an amino acid analysis describe protein supply and the synthetic capacity of the liver. They are medically useful but say nothing about folding quality inside cells. Targeted searching happens only on concrete suspicion, for example serum electrophoresis when light-chain amyloidosis is suspected. Offers promising to determine your proteostasis have no basis for it.

Can the protein quality control be supported through lifestyle?→

Not demonstrated in humans. The stimuli discussed are chiefly those that activate stress responses in model organisms: endurance training, heat exposure such as sauna, and periods without food intake that promote autophagy. For sauna and for physical activity there are observational data with favourable associations to cardiovascular health. That these effects arise through improved proteostasis is a plausible assumption without direct evidence. These measures remain sensible for other, well-documented reasons. A capsule claiming to activate chaperones, by contrast, has no evidence base.

Sources

  • Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nature Reviews Molecular Cell Biology. 2019;20(7):421–435.
  • Klaips CL, Jayaraj GG, Hartl FU. Pathways of cellular proteostasis in aging and disease. Journal of Cell Biology. 2018;217(1):51–63.
  • Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine. 2018;379(11):1007–1016.
  • López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243–278.